Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617

被引：0
|
作者：
Ferdinandus, J. [1 ]
Eppard, E. [1 ]
Kuerpig, S. [1 ]
Gaertner, F. [1 ]
Fimmers, R. [1 ]
Yordanova, A. [1 ]
Hauser, S. [1 ]
Essler, M. [1 ]
Feldmann, G. [1 ]
Ahmadzadehfar, H. [1 ]
机构：
[1] Univ Hosp Bonn, Bonn, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPW12
引用
收藏
页码：S212 / S213
页数：2
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
    Mehrens, Dirk
    Kramer, Kristina K. M.
    Unterrainer, Lena M.
    Beyer, Leonie
    Bartenstein, Peter
    Froelich, Matthias F.
    Tollens, Fabian
    Ricke, Jens
    Ruebenthaler, Johannes
    Schmidt-Hegemann, Nina-Sophie
    Herlemann, Annika
    Unterrainer, Marcus
    Kunz, Wolfgang G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (01): : 43 - +
  • [32] 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney
    Zhang, Jingjing
    Kulkarni, Harshad
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [33] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [34] Effect of 177Lu-PSMA-617 radioligand therapy on quality of life in patients with advanced metastatic prostate cancer
    Scheer, C.
    Juptner, M.
    Zhao, Y.
    Zuhayra, M.
    Lutzen, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S130 - S130
  • [35] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Braeuer, Axel
    Grubert, Lena Sophie
    Roll, Wolfgang
    Schrader, Andres Jan
    Schaefers, Michael
    Boegemann, Martin
    Rahbar, Kambiz
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1663 - 1670
  • [36] PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
    Widjaja, Liam
    Werner, Rudolf A.
    Ross, Tobias L.
    Bengel, Frank M.
    Derlin, Thorsten
    CANCERS, 2021, 13 (12)
  • [37] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Axel Bräuer
    Lena Sophie Grubert
    Wolfgang Roll
    Andres Jan Schrader
    Michael Schäfers
    Martin Bögemann
    Kambiz Rahbar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1663 - 1670
  • [38] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [39] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
    Groener, Daniel
    Baumgarten, Justus
    Davis, Karen
    Happel, Christian
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mader, Nicolai
    Mandel, Philipp
    Nikolaos, Tselis
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [40] 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
    Tonnelet, David
    Edet-Sanson, Agathe
    Augusto, Laetitia
    Cabourg, Marine
    Thureau, Sebastien
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E668 - E669
12345